An analyst recently raised the possibility of Pfizer Inc. acquiring $2.5 billion market cap Neurocrine Biosciences Inc. But other analysts who follow Neurocrine disagree that such an acquisition would take place in the near future, based on conversations with the biotechnology company’s management.
To read the entire story, you must be logged in.
Please log in now or register with us.
